Department of Chemistry and Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
PLoS One. 2009 Nov 10;4(11):e7738. doi: 10.1371/journal.pone.0007738.
T cells absorb nanometric membrane vesicles, prepared from plasma membrane of antigen presenting cells, via dual receptor/ligand interactions of T cell receptor (TCR) with cognate peptide/major histocompatibility complex (MHC) plus lymphocyte function-associated antigen 1 (LFA-1) with intercellular adhesion molecule 1. TCR-mediated signaling for LFA-1 activation is also required for the vesicle absorption. Exploiting those findings, we had established a high throughput screening (HTS) platform and screened a library for isolation of small molecules inhibiting the vesicle absorption. Follow-up studies confirmed that treatments (1 hour) with various mitochondrial antagonists, including a class of anti-diabetic drugs (i.e., Metformin and Phenformin), resulted in ubiquitous inhibition of the vesicle absorption without compromising viability of T cells. Further studies revealed that the mitochondrial drug treatments caused impairment of specific membrane-proximal TCR signaling event(s). Thus, activation of Akt and PLC-gamma1 and entry of extracellular Ca(2+) following TCR stimulation were attenuated while polymerization of monomeric actins upon TCR triggering progressed normally after the treatments. Dynamic F-actin rearrangement concurring with the vesicle absorption was also found to be impaired by the drug treatments, implying that the inhibition by the drug treatments of downstream signaling events (and the vesicle absorption) could result from lack of directional relocation of signaling and cell surface molecules. We also assessed the potential application of mitochondrial antagonists as immune modulators by probing effects of the long-term drug treatments (24 hours) on viability of resting primary T cells and cell cycle progression of antigen-stimulated T cells. This study unveils a novel regulatory mechanism for T cell immunity in response to environmental factors having effects on mitochondrial function.
T 细胞通过 T 细胞受体(TCR)与同源肽/主要组织相容性复合体(MHC)加淋巴细胞功能相关抗原 1(LFA-1)与细胞间黏附分子 1 的双重受体/配体相互作用,吸收来自抗原呈递细胞质膜的纳米级膜泡。TCR 介导的 LFA-1 激活信号对于囊泡吸收也是必需的。利用这些发现,我们建立了高通量筛选(HTS)平台,并筛选了一个文库以分离抑制囊泡吸收的小分子。后续研究证实,各种线粒体拮抗剂(包括一类抗糖尿病药物,即二甲双胍和苯乙双胍)的处理(1 小时)导致囊泡吸收普遍抑制,而不损害 T 细胞的活力。进一步的研究表明,线粒体药物处理导致特定的膜近端 TCR 信号事件(s)受损。因此,TCR 刺激后 Akt 和 PLC-gamma1 的激活和细胞外 Ca(2+)的进入被减弱,而 TCR 触发后单体肌动蛋白的聚合正常进行。药物处理后,与囊泡吸收一致的动态 F-肌动蛋白重排也被发现受损,这意味着药物处理对下游信号事件(和囊泡吸收)的抑制可能是由于信号和细胞表面分子的定向重定位缺失所致。我们还通过探测长期药物处理(24 小时)对静息原代 T 细胞活力和抗原刺激的 T 细胞细胞周期进程的影响,评估了线粒体拮抗剂作为免疫调节剂的潜在应用。本研究揭示了 T 细胞免疫对影响线粒体功能的环境因素的一种新的调节机制。